Contrast Agents: Market Trends, Technologies and Industrial Challenges

A Rapidly Growing Global Market

Medical imaging continues to expand steadily, driven by the rise in chronic diseases, the demand for earlier diagnosis, and the emergence of new technologies. At the center of this dynamic are contrast agents, essential for more than half of all CT scans and over 40% of MRI procedures.

The global contrast agents market is projected to reach $7.4 billion by 2026, with an estimated annual growth rate of 6–8%.
Every year, more than 400 million doses are administered worldwide, underscoring the strategic importance of these products for healthcare systems.

A defining feature of the sector is its high level of concentration: around 75% of the global market is held by just five players, highlighting the vulnerability of the supply chain and the need for reliable industrial partners capable of securing critical volumes.

Overview of Available Technologies

Iodinated contrast agents (65–70% of the market) remain indispensable in CT imaging, with molecules such as iohexol, iopamidol, and iomeprol representing a large share of global volumes and still showing significant growth for some of them.

In MRI, the shift toward safer gadolinium‑based macrocyclic agents continues. Several next‑generation molecules are experiencing double‑digit growth, reflecting rapid adoption by imaging centers and an increasing demand for improved diagnostic performance.

Contrast‑enhanced ultrasound is gaining relevance thanks to microbubbles, particularly in specialized indications such as hepatic imaging, where they significantly improve the detection of lesions that remain difficult to visualize using conventional imaging.

Finally, alternative agents such as CO₂, USPIO, or manganese‑based products are being explored to meet specific needs related to tolerability or biological targeting.

Structural Market Trends

The sector is evolving toward safer, better‑tolerated and more stable contrast agents, particularly in MRI, where linear gadolinium chelates have been progressively phased out due to safety concerns and replaced with much more stable macrocyclic complexes.

At the same time, clinical practice is moving toward fine‑tuned dose optimization, driven by clinical guidelines requiring adjustments based on patient weight, kilovoltage and examination type. This shift results in stricter expectations around formulation and pharmaceutical‑grade ingredient quality.

Recent reforms in the procurement of contrast agents have also reshaped the landscape: healthcare providers must now purchase these products directly, increasing the importance of a robust and secure supply chain to accommodate rising volumes and prevent critical shortages.

Finally, the market is undergoing increased segmentation, with some historical molecules declining while others are expanding rapidly, reshaping the balance among CT, MRI, ultrasound and specialized applications.

CDMOs: Essential Industrial Partners in a Transforming Imaging Market

In a sector where quality, purity and reliability are essential to ensure patient safety, SEQENS plays a pivotal role thanks to its unique combination of scientific expertise, industrial know‑how and excellence in pharmaceutical quality.

Advanced Expertise in Complex Syntheses for Contrast Agents

SEQENS brings recognized know‑how in carrying out key steps required for the production of critical intermediates used in iodinated, gadolinium‑based and emerging contrast agents:

• Advanced purification, ensuring strict control of organic and metallic impurities as well as intermediate stability through multi‑step purification processes and high‑level analytical monitoring.
• Cyclization, essential for forming macrocyclic structures used in next‑generation gadolinium‑based agents, with precise control over yields, by‑products and scale‑up.
• Selective chlorination, a key competency for synthesizing aromatic intermediates used in iodinated contrast media, executed under robust and safe industrial conditions.
• Oxidation/reduction, a cornerstone of multi‑step synthesis routes, enabling complex functional transformations with precision, safety and reproducibility.

This combination of capabilities allows SEQENS to meet the highest standards of purity, safety and process robustness, all crucial for manufacturing modern contrast agents.

Pharmaceutical‑Scale Industrialization Capacity

The company offers scalable production capabilities from kilogram to ton scale, a major asset in a market where demand is rising rapidly and where any supply interruption can affect access to care.

A Reliable, Local and Resilient Supply Chain

With multi‑site industrial operations across Europe and North America, SEQENS provides a robust and secure supply chain fully aligned with evolving regulatory and logistical requirements in the medical imaging sector.

A Strong Commitment to Green Chemistry and Sustainability

SEQENS is fully committed to the transition toward more sustainable contrast agents through initiatives in green chemistry, energy optimization, solvent reduction and improved environmental performance of its processes.

A Dynamic Market, Creating Opportunities for Leading CDMOs

As the contrast agents market continues to expand—driven by clinical needs, technological innovation and evolving regulations—SEQENS positions itself as a strategic partner.
With its mastery of complex chemistry, operational excellence and ability to secure the availability of critical molecules, SEQENS provides long‑term support to industry players in the development and production of the next generation of contrast agents.